ZA913353B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA913353B
ZA913353B ZA913353A ZA913353A ZA913353B ZA 913353 B ZA913353 B ZA 913353B ZA 913353 A ZA913353 A ZA 913353A ZA 913353 A ZA913353 A ZA 913353A ZA 913353 B ZA913353 B ZA 913353B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
core
prostaglandin
coating
nsaid
Prior art date
Application number
ZA913353A
Other languages
English (en)
Inventor
Rene Antoine Gimet
Antoine Gimet Rene
Jean Charles Jinot
Charles Jinot Jean
Christian Magnet
Magnet Christian
Isabelle Maroteaux
Maroteaux Isabelle
Francoise M Nevoux
M Nevoux Francoise
Roger Scoyer
Scoyer Roger
Barbara J Struthers
J Struthers Barbara
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24063571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA913353(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of ZA913353B publication Critical patent/ZA913353B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA913353A 1990-05-03 1991-05-03 Pharmaceutical composition ZA913353B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51835390A 1990-05-03 1990-05-03

Publications (1)

Publication Number Publication Date
ZA913353B true ZA913353B (en) 1993-04-28

Family

ID=24063571

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA913353A ZA913353B (en) 1990-05-03 1991-05-03 Pharmaceutical composition

Country Status (15)

Country Link
US (2) US5601843A (fr)
EP (1) EP0527887B1 (fr)
AT (1) ATE121625T1 (fr)
AU (1) AU7876491A (fr)
CA (1) CA2082944C (fr)
DE (1) DE69109286T2 (fr)
DK (1) DK0527887T3 (fr)
ES (1) ES2071312T3 (fr)
GR (1) GR3015939T3 (fr)
IE (1) IE68596B1 (fr)
IL (1) IL98033A (fr)
NZ (1) NZ238024A (fr)
PT (1) PT97562B (fr)
WO (1) WO1991016895A1 (fr)
ZA (1) ZA913353B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071312T3 (es) * 1990-05-03 1995-06-16 Searle & Co Composicion farmaceutica.
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
US5324746A (en) * 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
AU6981996A (en) * 1995-09-27 1997-04-17 Merck Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
KR20010021625A (ko) 1997-07-09 2001-03-15 추후보정 개선된 남성발기 기능장애 치료방법 및 그 조성물
CA2241342C (fr) * 1998-06-15 2000-02-08 Bernard Charles Sherman Comprimes pharmaceutiques contenant un anti-inflammatoire non steroidien et une prostaglandine
GB9814215D0 (en) * 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) * 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
SE9803761D0 (sv) * 1998-11-04 1998-11-04 Synphora Ab Method to avoid increased iridial pigmentation during prostaglandin treatment
US7429407B2 (en) * 1998-12-30 2008-09-30 Aeromatic Fielder Ag Process for coating small bodies, including tablets
CA2259727A1 (fr) * 1999-01-18 2000-07-18 Bernard Charles Sherman Pastille pharmaceutique a deux couches comprenant un ains et du misoprostol
US6183779B1 (en) 1999-03-22 2001-02-06 Pharmascience Inc. Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
CA2277407A1 (fr) 1999-07-14 2001-01-14 Bernard Charles Sherman Comprime comprenant un ains et du misoprostol
AU7537000A (en) * 1999-10-01 2001-05-10 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2004064815A1 (fr) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Formulation de dosage oral
ATE366105T1 (de) * 2003-03-03 2007-07-15 Sprl Franpharma Stabilisierte pharmazeutische zusammensetzung enthaltend einen nsaid und einen prostaglandin
WO2004091579A1 (fr) * 2003-04-16 2004-10-28 Pharmacia Corporation Formulation de prostaglandine stabilisee
US7241746B2 (en) 2003-08-06 2007-07-10 Regena Therapeutics, Lc Method and composition for treating periodontal disease
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20060073202A1 (en) * 2004-10-05 2006-04-06 Rocca Jose G Dual component medicament delivery system
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) * 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US20150224056A1 (en) * 2006-07-18 2015-08-13 Horizon Pharma Usa, Inc. Pharmaceutical compositions of ibuprofen and famotidine
EP2063873A2 (fr) * 2006-08-31 2009-06-03 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
EP2167048B1 (fr) 2007-05-30 2016-10-26 Wockhardt Limited Nouvelle forme posologique de comprimé
CA2736547C (fr) 2008-09-09 2016-11-01 Pozen Inc. Procede d'administration d'une composition pharmaceutique a un patient en ayant besoin
EP2210595A1 (fr) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Revêtement actif de formes de dosage pharmaceutique
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
KR20180128452A (ko) * 2016-04-11 2018-12-03 유니버시티 오브 유타 리서치 파운데이션 Nsaid-유도된 심혈관, 뇌혈관, 또는 신혈관 부작용을 치료하는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2135881A (en) * 1983-03-02 1984-09-12 Erba Farmitalia Method and pharmaceutical compositions for inhibiting or reducing gastrointestinal side effects of non-steroidal anti-inflammatory drugs
IT1190400B (it) * 1985-10-04 1988-02-16 Istituto Biochimico Italiano Derivati dell'acido 19,20-bis,nor-prostanoico ad attivita' antiulcera e anoressivca,procedimento per la loro preparazione e composizioni farmaceutiche
US4707495A (en) * 1985-10-28 1987-11-17 Ortho Pharmaceutical Peptic ulcer treatment method
US4975283A (en) * 1985-12-12 1990-12-04 Bristol-Myers Squibb Company Stabilized enteric coated aspirin granules and process for preparation
DE3603576A1 (de) * 1986-02-06 1987-08-13 Code Kaffee Handel Verwendung von gerbstoffen und/oder chlorogensaeure sowie nahrungs-, genuss- und/oder arzneimittel mit gerbstoff- und/oder chlorogensaeurezusatz
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
ES2071312T3 (es) * 1990-05-03 1995-06-16 Searle & Co Composicion farmaceutica.

Also Published As

Publication number Publication date
ES2071312T3 (es) 1995-06-16
EP0527887A1 (fr) 1993-02-24
EP0527887B1 (fr) 1995-04-26
CA2082944C (fr) 1998-11-24
IL98033A (en) 1995-07-31
GR3015939T3 (en) 1995-07-31
US5698225A (en) 1997-12-16
IE911486A1 (en) 1991-11-06
IL98033A0 (en) 1992-06-21
IE68596B1 (en) 1996-06-26
PT97562A (pt) 1992-02-28
ATE121625T1 (de) 1995-05-15
CA2082944A1 (fr) 1991-11-04
DE69109286D1 (de) 1995-06-01
DK0527887T3 (da) 1995-07-03
NZ238024A (en) 1993-08-26
WO1991016895A1 (fr) 1991-11-14
PT97562B (pt) 1998-08-31
DE69109286T2 (de) 1995-09-28
US5601843A (en) 1997-02-11
AU7876491A (en) 1991-11-27

Similar Documents

Publication Publication Date Title
ZA913353B (en) Pharmaceutical composition
NO923947D0 (no) Smaksmaskering av ibuprofen ved fluidlagbelegning
MX9605646A (es) Preparacion de nifedipino de liberacion prolongada.
NO911934L (no) Fremgangsmaate for fremstilling av bicykliske 1-aza-cykloalkaner.
AR244918A1 (es) Un amplificador optico del tipo de fibra activa
DK0643705T3 (da) Fremgangsmåde til fremstilling af N-beta-hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- og N-beta-hydroxyal
ES2089423T3 (es) Percarbonato de sodio.
FR2687753B1 (fr) Soufflet notamment pour joints homocinetiques.
FR2670865B1 (fr) Lampe pour salle d'operation.
BE890847A (fr) Electro-aimant, notamment pour l'actionnement d'une valve
HU9500818D0 (en) Retarde compositions containing alfuzonin-hydrochloride
RS49598B (sr) Intermedijari i proces za dobijanje olanzapina
JO1704B1 (en) New potent compounds
ZA925469B (en) Process for chiral thiazolidine-2,4-dione hypoglycemics and intermediates
AU3234789A (en) 2-(2-(substituted)pyrid-3-yl oxy)-4,6-dimethoxy-pyrimidines
ES8301928A1 (es) Un procedimiento para preparar 4-(2-4-dicloro-3-metilbenzoil)-1,3-dimetil-5-fenaciloxipirazol).
DE69200867D1 (de) Betätigungseinrichtung eines Getriebes.
IL117097A0 (en) Substituted heterocycloalkenes their preparation and use
DE69930952D1 (de) Gesteuerte freisetzung von antidepressiva
FR2690766B1 (fr) Interface programmable notamment pour la commande d'installations domestiques.
AU9178198A (en) Diamond core with a diamond coating
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
RU1825905C (ru) Кольцева пружина Н.Н.Рахманова
SU637584A1 (ru) Кран
SU1829367A1 (ru) 5-(1-гидрокси-1-метоксикарбонил-2,2,2-трифторэтил)-8-трибутилоловооксихинолин, проявляющий антистафилококковую активность